Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma - Agache, I; Beltran, J; Akdis, C (Allergy, 2020)
. doi:343917 de-38m